Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.

Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):99-106. doi: 10.1007/s11255-013-0386-2. Epub 2013 Jan 25.

PMID:
23355029
2.

Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).

Westerberg PA, Tivesten Å, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Larsson TE, Linde T, Ljunggren Ö.

BMC Nephrol. 2013 Apr 15;14:85. doi: 10.1186/1471-2369-14-85.

3.

Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H.

Atherosclerosis. 2014 Nov;237(1):53-9. doi: 10.1016/j.atherosclerosis.2014.08.037. Epub 2014 Aug 28.

PMID:
25200615
4.

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.

Bone. 2012 Jun;50(6):1266-74. doi: 10.1016/j.bone.2012.02.634. Epub 2012 Mar 6.

PMID:
22425694
5.

Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?

Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Larsson TE.

Nephrol Dial Transplant. 2010 Sep;25(9):3033-8. doi: 10.1093/ndt/gfq191. Epub 2010 Apr 5.

PMID:
20368304
6.

Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.

Mizuiri S, Nishizawa Y, Yamashita K, Ono K, Oda M, Usui K, Shigemoto K.

Nephrology (Carlton). 2014 Sep;19(9):568-73. doi: 10.1111/nep.12290.

7.

Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.

Marsell R, Grundberg E, Krajisnik T, Mallmin H, Karlsson M, Mellström D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE.

Eur J Endocrinol. 2008 Jan;158(1):125-9. doi: 10.1530/EJE-07-0534.

8.

Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.

Kuczera P, Adamczak M, Wiecek A.

Clin Endocrinol (Oxf). 2014 Apr;80(4):607-12. doi: 10.1111/cen.12326. Epub 2013 Oct 10.

PMID:
24111496
9.

Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.

Clin J Am Soc Nephrol. 2012 May;7(5):810-9. doi: 10.2215/CJN.08680811. Epub 2012 Feb 23.

10.

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.

Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S, Calvo N, De la Orden V, De la Flor JC, Valga F, Vidaurreta M, Fernández-Pérez C, Barrientos A.

Nephrol Dial Transplant. 2012 Nov;27(11):4227-35. doi: 10.1093/ndt/gfs409.

PMID:
23144073
11.

Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE.

Clin J Am Soc Nephrol. 2013 May;8(5):781-6. doi: 10.2215/CJN.09570912. Epub 2013 Jan 18.

12.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.

Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9. Erratum in: Kidney Int. 2012 Aug;82(4):498.

13.

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.

Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.

J Nephrol. 2015 Aug;28(4):477-84. doi: 10.1007/s40620-015-0178-0. Epub 2015 Feb 21.

14.

Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.

Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):315-22. doi: 10.1111/j.1744-9987.2009.00796.x.

PMID:
20609185
15.

Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.

Asamiya Y, Yajima A, Shimizu S, Otsubo S, Tsuchiya K, Nitta K.

Osteoporos Int. 2015 Mar;26(3):1017-28. doi: 10.1007/s00198-014-2934-8. Epub 2014 Nov 4.

PMID:
25366373
17.

Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.

Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH; NIGRAM Consortium..

Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78. doi: 10.2215/CJN.01880213. Epub 2013 Aug 8.

18.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*..

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

19.

Abnormalities in renal tubular phosphate handling in children with sickle cell disease.

Raj VM, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C, Katsoufis C, Chandar J, Ruiz P, Zilleruelo G.

Pediatr Blood Cancer. 2014 Dec;61(12):2267-70. doi: 10.1002/pbc.25188. Epub 2014 Aug 17.

PMID:
25132581
20.

Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.

Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, Narita I.

Nephron. 2015;131(3):161-6. doi: 10.1159/000440968. Epub 2015 Nov 6.

Supplemental Content

Support Center